U.S. Tremfya Market Size, Share, Trends, Industry Analysis Report By Application [Plaque Psoriasis, Psoriatic Arthritis (PsA), Others], By Distribution Channel - Market Forecast, 2025-2034

The U.S. Tremfya market size is expected to reach USD 5.45 billion by 2034, according to a new study by Polaris Market Research. The report "U.S. Tremfya market Size, Share, Trends, Industry Analysis Report By Application [Plaque Psoriasis, Psoriatic Arthritis (PsA), Others], By Distribution Channel - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The U.S. Tremfya market encompasses the commercial activities surrounding guselkumab, a biologic medication. This drug, sold under the brand name Tremfya, selectively targets the interleukin-23 (IL-23) pathway, which is a key component in the inflammatory processes of various autoimmune diseases. Its primary applications include the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and more recently, moderately to severely active Crohn's disease and ulcerative colitis. The market includes its development, manufacturing, distribution through various channels, and prescription for eligible patients across the U.S.

The U.S. Tremfya market has seen significant growth, driven by a combination of factors. The increasing number of people affected by chronic autoimmune conditions such as plaque psoriasis and psoriatic arthritis creates a consistent and growing patient pool seeking effective, long-term treatments. Furthermore, the drug's strong clinical efficacy in providing significant symptom relief, coupled with its expanding regulatory approvals for new indications such as inflammatory bowel diseases, broadens its market potential considerably. This strong clinical profile and wider applicability are key to Tremfya's rising adoption among healthcare providers and patients.

U.S. Tremfya Market Report Highlights

By application, the plaque psoriasis segment held the largest share of the U.S. Tremfya market due to the high prevalence of moderate to severe plaque psoriasis among the population. Tremfya has demonstrated significant effectiveness in achieving skin clearance in clinical studies, making it a preferred choice for patients and healthcare providers dealing with this widespread chronic condition.

By distribution channel, the hospital pharmacies segment held the largest share in 2024. This dominance stems from the specialized nature of biologic drugs such as Tremfya, which often require careful handling, specific administration protocols, and direct oversight by medical professionals, all of which are well-supported within the structured environment of hospital pharmacies.

Johnson & Johnson who is the current manufacturer of Tremfya.

Polaris Market Research has segmented the U.S. Tremfya market report on the basis of application and distribution channel:

By Application Outlook (Revenue - USD Billion, 2020-2034)

Plaque Psoriasis

Psoriatic Arthritis (PsA)

Others

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies